"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Michael R. Folkert, MD, PhD
Advertisement
Articles by Michael R. Folkert, MD, PhD
Advertisement
Latest Updated Articles
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancerPublished: March 17th 2025 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
